NeuroRx, a pharmaceutical company, went public via a SPAC merger with Big Rock Partners Acquisition, a special purposes acquisition company, in a $500m deal. "Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of "Bringing Hope to Life," Jonathan C. Javitt, NeuroRx Founder, Chairman & CEO.